Insilico Medicine and Ribo enter strategic collaboration agreement: Leveraging AI platform and automated lab for end-to-end empowerment of RNA interference and oligonucleotide therapeutics development
https://www.eurekalert.org/news-releases/1127637
Publish Date: 2026-05-12 09:16:00
Source Domain: www.eurekalert.org
- Strategic Collaboration Announcement: Insilico Medicine and Suzhou Ribo Life Science Co. have announced a strategic collaboration aimed at boosting oligonucleotide drug research and development efficiency.
- Integration of Technologies: The collaboration leverages Insilico’s advanced Pharma.AI platform and Ribo’s expertise in oligonucleotide therapeutics development, enhancing the overall research and development process.
- Enhanced Efficiency in R&D Cycle: The partnership aims to significantly speed up and improve the oligonucleotide drug research and development cycle through the combination of AI-driven insights and Ribo’s extensive technological platforms.
- First Partner for LifeStar 2 Lab: Ribo has been designated as the first partner for high-throughput experimental services utilizing Insilico’s LifeStar 2 automated laboratory platform, highlighting the industrial significance of this collaboration.
- Focus on Global Health Benefits: Both companies emphasize the potential global impact of the collaboration, aiming to develop AI-driven oligonucleotide therapies to benefit humanity by addressing unmet clinical needs.
